These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23291388)
1. Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Latourte A; Frazier A; Brière C; Ea HK; Richette P Ann Rheum Dis; 2013 May; 72(5):783-4. PubMed ID: 23291388 [No Abstract] [Full Text] [Related]
2. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Naumann L; Feist E; Natusch A; Langen S; Krause A; Buttgereit F; Burmester GR Ann Rheum Dis; 2010 Feb; 69(2):466-7. PubMed ID: 20107032 [No Abstract] [Full Text] [Related]
3. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Moltó A; Ea HK; Richette P; Bardin T; Lioté F Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Seitz M; Kamgang RK; Simon HU; Villiger PM Ann Rheum Dis; 2005 Dec; 64(12):1802-3. PubMed ID: 16284353 [No Abstract] [Full Text] [Related]
5. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502 [TBL] [Abstract][Full Text] [Related]
6. Successful use of anakinra to treat refractory Schnitzler's syndrome. Dybowski F; Sepp N; Bergerhausen HJ; Braun J Clin Exp Rheumatol; 2008; 26(2):354-7. PubMed ID: 18565263 [TBL] [Abstract][Full Text] [Related]
7. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945 [TBL] [Abstract][Full Text] [Related]
9. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Furlan A; Botsios C; Ruffatti A; Todesco S; Punzi L Joint Bone Spine; 2008 May; 75(3):366-7. PubMed ID: 18068393 [No Abstract] [Full Text] [Related]
10. [Anakinra in refractory adult onset Still's disease]. Vercoutere W; Starmans-Kool M; Peeters RM Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723 [TBL] [Abstract][Full Text] [Related]
11. Chronic urticaria and arthritis with polyclonal IgA: rapid response and clinical remission with interleukin 1 blockade. Chu CQ J Rheumatol; 2010 Apr; 37(4):881-2. PubMed ID: 20360207 [No Abstract] [Full Text] [Related]
12. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Brenner M; Ruzicka T; Plewig G; Thomas P; Herzer P Br J Dermatol; 2009 Nov; 161(5):1199-201. PubMed ID: 19673875 [TBL] [Abstract][Full Text] [Related]
13. The many worlds of reducing interleukin-1. Dinarello CA Arthritis Rheum; 2005 Jul; 52(7):1960-7. PubMed ID: 15986340 [No Abstract] [Full Text] [Related]
14. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Lutz V; Lipsker D Arch Dermatol; 2012 Mar; 148(3):297-9. PubMed ID: 22431771 [No Abstract] [Full Text] [Related]
15. Joint disease in haemochromatosis. Hamilton E Mod Trends Rheumatol; 1971; 2():338-47. PubMed ID: 5155326 [No Abstract] [Full Text] [Related]